Drugs / Triumeq
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Triumeq | — | 2014-08-31 | europa.eu ↗ |
| Approved | US (FDA) | TRIUMEQ | — | 2014-08-22 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT02354053 | Nov 2015 → Jul 2018 | HIV infectious disease | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02924389 Background | Sep 2016 → Sep 2019 | HIV infectious disease | Emory University | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 3
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triumeq | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02354053 ↗ |
| Route | Oral | “Triumeq will be taken orally once daily.” NCT02924389 ↗ |